QH103 Cell Therapy for Resistant Autoimmune Nerve and Brain Diseases
Treatments studied
Part of Bones, joints & muscles, Brain & nervous system, Cancer, Eyes & vision, Immune system & allergy clinical trials.
This Phase 1 trial tests whether QH103 cell injections can help patients with serious autoimmune diseases affecting nerves and the brain (like MS, NMOSD, myasthenia gravis, and others) that haven't responded well to standard treatments. The goal is to evaluate safety and whether the treatment helps reduce symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18–75 years old
- Have one of seven specific autoimmune nerve or brain diseases that is resistant to standard treatments
- Meet disability and symptom severity thresholds specific to your condition (measured by EDSS, mRS, MG-ADL, or similar scales)
- Have adequate blood cell counts, liver, kidney, heart, and blood clotting function
- Not be pregnant or breastfeeding; agree to use birth control for at least 6 months after treatment
- Not have active infections, cancer in past 5 years, hepatitis B/C, HIV, or certain psychiatric conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immune-cell therapy (CAR-T) for people with certain autoimmune diseases of the brain and spinal cord that have not improved with standard treatments. The therapy aims to reset the immune system to stop it from attacking the nervous system.
This early-phase trial tests CT103A “CAR-T” cell therapy to treat certain relapsing or treatment-resistant autoimmune diseases that affect the nervous system. It aims to see whether the cells are safe and may help reduce disease activity when standard treatments haven’t controlled symptoms.
This trial tests a new medicine (NouvSoma001) for people with neuromyelitis optica (NMOSD) who are having a flare-up. The goal is to see if the treatment is safe and if it helps reduce symptoms like pain and trouble moving.
This study is a long-term observational study—it does not test a new drug but follows people with certain nerve and immune conditions (like multiple sclerosis, myasthenia gravis, and others) to learn more about how these diseases progress. By joining, you help researchers gather valuable data that could improve care for others with similar conditions.
This early-phase trial tests a new type of immune cell therapy (CAR-T) designed to target and calm the immune system in people with certain autoimmune neurological diseases that haven't improved with standard care. The goal is to see if it's safe and if it can reduce disease activity.
This trial tests a new cell-based treatment (called HY001N) for people with certain autoimmune neurological diseases that have not responded to standard treatments. The treatment aims to reset the immune system to reduce attacks and improve symptoms.
Hear when a new Multiple Sclerosis (MS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.